Skip to main content

Table 4 Acute toxicities in the 394 NPC patients

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Acute toxicity NTZ group
N = 50 (%)
Non-NTZ group
N = 344 (%)
P value
Leukopenia 0.739
 G0–G1 18 (36.00) 129 (37.50)  
 G2 14 (28.00) 100 (29.07)  
 G3 14 (28.00) 91 (26.45)  
 G4 4 (8.00) 24 (6.98)  
Neutropenia 0.947
 G0–G1 26 (52.00) 173 (50.29)  
 G2 13 (26.00) 98 (28.49)  
 G3 10 (20.00) 73 (21.22)  
 G4 1 (2.00) 0  
Anemia 0.811
 G0–G1 40 (80.00) 279 (81.10)  
 G2 7 (14.00) 51 (14.83)  
 G3 3 (6.00) 14 (4.07)  
Thrombocytopenia 0.650
 G0–G1 45 (90.00) 316 (91.86)  
 G2 4 (8.00) 24 (6.98)  
 G3 1 (2.00) 4 (1.17)  
Hepatotoxicity 0.760
 G0–G1 43 (86.00) 290 (84.30)  
 G2 5 (10.00) 39 (11.34)  
 G3 2 (4.00) 15 (4.36)  
Nephrotoxicity 0.671
 G0–G1 47 (94.00) 318 (92.44)  
G2 3 (6.00) 19 (5.52)  
 G3 0 7 (2.03)  
Skin reaction 0.866
 G0–G1 37 (74.00) 257 (74.71)  
 G2 11 (22.00) 79 (22.97)  
 G3 2 (4.00) 8 (2.33)  
Mucositis 0.594
 G0–G1 16 (32.00) 117 (34.01)  
 G2 19 (38.00) 139 (40.41)  
 G3 13 (26.00) 76 (22.09)  
 G4 2 (4.00) 12 (3.49)  
Nausea 0.895
 G0–G1 27 (54.00) 178 (51.74)  
 G2 17 (34.00) 130 (37.79)  
 G3 4 (8.00) 31 (9.01)  
 G4 2 (4.00) 5 (1.45)  
Vomiting 0.803
 G0–G1 35 (70.00) 233 (67.73)  
 G2 9 (18.00) 72 (20.93)  
 G3 6 (12.00) 39 (11.34)  
Diarrhea 0.693
 G0–G1 44 (88.00) 309 (89.83)  
 G2 6 (12.00) 35 (10.17)  
Weight loss 0.623
 G0–G1 38 (76.00) 271 (78.78)  
 G2 10 (20.00) 65 (18.90)  
 G3 2 (4.00) 8 (2.33)